Site Termination Sample Clauses

Site Termination. If ImmunoGen, an Investigator, or regulatory authorities discover conditions during the study that indicate that the study or related activities at a particular center should be terminated, this action may be taken after appropriate consultation between ImmunoGen and the Investigator. Conditions that may warrant study or center termination include but are not limited to: • Discovery of an unexpected, serious, and/or unacceptable risk to patients enrolled in the study • Decision on the part of ImmunoGen to suspend or discontinue testing, evaluation, or development of the clinical program • Unacceptable benefit-risk relationship of the investigational product • Recommendations of the IDMC or regulatory body • Investigator failure to comply with applicable regulatory authority requirements or protocol requirements • Submission of knowingly false information from the center to ImmunoGen or regulatory authorities Study or center termination and follow-up will be performed in compliance with the conditions set forth in 21 CFR Section 312 and in compliance with the principles set forth in International Conference on Harmonisation (ICH) Good Clinical Practices (GCPs).

Site Termination. A mentor teacher or school administrator may initiate an intervention and/or termination of a placement after consultation with the UAH university supervisor and/or Coordinator of Field and Clinical Experiences. UAH recognizes that candidates must comply with all LEA policies and procedures and will so instruct its candidates. When a violation of policy occurs, the LEA will notify UAH of the concern(s), and, if requested by the LEA, UAH will remove the candidate from the setting, thus terminating the placement. UAH will notify the LEA if it determines that a candidate must be removed for any reason. These reasons can be, but are not limited to: tardiness, absences, grades, or unacceptable performance or behavior. A letter explaining the placement termination will be sent by UAH to the mentor teacher and/or school administrator. Electronic mail is acceptable.

Site Termination. The User agrees that the Company has the right to immediately suspend your Personal Account, block Personal Account, as well as suspend the User's access to MinePlex platform for any reason, including suspicions of violation by the User of this Agreement, Privacy Policy or any applicable laws, regulations, contracts or agreements. The user agrees that the Company is not responsible for permanent or temporary change, suspension or termination actions of the User's Personal Account or access to all or any parts of services. The following list represents the reasons why The Company may apply the actions described above (the list is not is exceptional): The following list represents the reasons why the Company may terminate this Agreement directly, by canceling the User's Personal Account: User agreement: MINEPLEX PTE. LTD. Address: ▇▇ ▇▇▇▇▇ ▇▇▇▇ # ▇▇-▇▇ ▇▇▇▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇ 1 Re-registration on behalf of another person as MinePlex user; Providing false, inaccurate, outdated information when registering a Personal Account; For any other circumstances, at the discretion of the Company; The user violates or may violate international the Company's obligations to comply with legal and regulatory documents, requirements of the MAS regulator; User when using the Personal Account or website Companies violated international law, the laws of Singapore or the laws of the country in which he is located and/or whose resident he is; The user is included in the list of persons subject to international sanctions, or is located/registered in the territory, subject to international sanctions.

Site Termination. 5.1 The Province may terminate all Site Access at a Site immediately, upon notice to the Signing Authority for the Site, if: (a) the Approved SSO for the Site is no longer approved by the Province to provide information technology hardware, software, or service in connection with PharmaNet, or (b) the Province determines that the SSO-Provided Technology or Associated Technology in use at the Site, or any component thereof, is obsolete, unsupported, or otherwise poses an unacceptable security risk to PharmaNet, and the Organization is unable or unwilling to remedy the problem within a timeframe acceptable to the Province. 5.2 As a security precaution, the Province may suspend Site Access at a Site after a period of inactivity. If Site Access at a Site remains inactive for a period of 90 days or more, the Province may, immediately upon notice to the Signing Authority for the Site, terminate all further Site Access at the Site. 5.3 Organization must prevent all further Site Access at termination, in accordance with this Article 5, of Site Access at the Site.

Site Termination. Lupin Inc. may, in its sole discretion, terminate a single study site for various reasons, including, but not limited to, the following: • Failure of the Investigator to enroll subjects into the study at a reasonable rate • Failure of the Investigator to comply with pertinent FDA regulations • Submission of knowingly false information from the research facility to the Sponsor, Study Monitor, or FDA • Insufficient adherence to protocol requirements If the participation of a study site is terminated for reasons other than safety (e.g., uncorrected data acquisition or image quality issues), Lupin Inc. will issue a written notice to the Investigator. The written notice will contain the reasons for taking such action. If a study site is terminated for noncompliance, Lupin Inc. will also notify appropriate regulatory authorities. Study termination and follow up will be performed in compliance with the conditions set forth in 21 CFR 312.50 and 21 CFR 312.56.